Table 6 Sensitivity analyses: evaluation of different lengths of the latency period and a cohort age restriction, using time-dependent exposure and the recency-weighted duration of exposure metrics, with time to lung cancer as the outcome

  Time-Dependent Statin Exposure^a

1.00

0.87

1.16

0.9698

  Recency-Weighted Duration of Use^b

1.04

0.97

1.12

0.2754

  Time-Dependent Statin Exposure

0.96

0.82

1.12

0.5808

  Recency-Weighted Duration of Use

1.00

0.92

1.08

0.9214

  Time-Dependent Statin Exposure

0.85

0.73

1.00

0.05

  Recency-Weighted Duration of Use

0.85

0.77

0.93

0.0006

  Time-Dependent Statin Exposure

0.62

0.52

0.73

< 0.0001

  Recency-Weighted Duration of Use

0.57

0.49

0.66

< 0.0001

  Time-Dependent Statin Exposure

0.72

0.60

0.86

0.0004

  Recency-Weighted Duration of Use

0.78

0.70

0.87

< 0.0001